Skip to main content
Caplight Logo









Vast Therapeutics

Vast Therapeutics

Private
Morrisville, North CarolinaHealthcare & Life Scienceshttps://www.vasttherapeutics.com/

Last Round

Grant

Sep 16, 2025

Est. Valuation

$49.85M

Total Funding Raised

$35.13M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vast Therapeutics is a clinical-stage life sciences company that develops nitric oxide-based medicines for patients with chronic respiratory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

nitric oxide therapyinhaled therapeuticsrespiratory diseasecystic fibrosis treatmentnebulized drugbronchiectasisNTM lung diseasesustained-release deliverybiotech startupclinical-stage pharmadrug developmentpulmonary medicinenon-antibiotic therapyorphan drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vast Therapeutics Comparables

Compare Vast Therapeutics with similar companies based on industry and business-model similarity.

Vast Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Novoteris, LLC
88%
Revagenix, Inc.
76%
Matinas BioPharma Holdings, Inc.
70%

Vast Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 16, 2025
Series BMar 17, 2025
GrantJan 21, 2025
GrantJan 16, 2019
Series AJan 16, 2019
Grant
Dec 13, 2018

Vast Therapeutics Investors

Notable investors and investment history

Vast Therapeutics investors
InvestorRounds
Shionogi & Co.Series A
NIH RADxGrant
Cystic Fibrosis FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 82% MoM.

  • Sep 16, 2025

    Secured $2M from NIH RADx.

Vast Therapeutics Filings

Explore SEC and related filing metadata, where available.

Vast Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Vast Therapeutics's valuation, stock price, and market status.

Is Vast Therapeutics a public or private company?

Vast Therapeutics is a private company.

What is the current stock price of Vast Therapeutics?

Vast Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Vast Therapeutics worth (valuation)?

Vast Therapeutics's valuation is estimated at $49.9M based on funding round data.

Can I buy Vast Therapeutics stock?

Vast Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Vast Therapeutics's last funding round?

Vast Therapeutics's most recent funding round was Grant on March 17, 2025.

Who are the main investors in Vast Therapeutics?

Key investors in Vast Therapeutics include NIH RADx, Cystic Fibrosis Foundation.

Will Vast Therapeutics IPO soon?

No public IPO plans have been announced for Vast Therapeutics.

How can I track Vast Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vast Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMorrisville, North Carolina
Employee Range11
Year Founded2017
Last FundingSep 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?